AMED - Morgan Stanley likes BeiGene in premarket analyst action January, 17 2020 07:02 AM Amedisys Inc Amedisys (NASDAQ:AMED) initiated with Outperform rating and $206 (14% upside) price target at Credit Suisse.More news on: Amedisys, Inc., BeiGene, Ltd., Karyopharm Therapeutics Inc., Healthcare stocks news, , Read more ...